Regor Therapeutics

Executive Summary

Regor Therapeutics is a private China-based biotechnology company leveraging its proprietary rCARD (computer-accelerated rational discovery) platform for AI-driven small molecule drug discovery. Founded in 2020 and headquartered in Suzhou, the company focuses on oncology, metabolism, and immunology. Regor's business model centers on identifying and optimizing preclinical candidates and then out-licensing these validated assets to major pharmaceutical partners for clinical development and commercialization. As of early 2026, Regor has advanced several programs into preclinical development, with a lead candidate in oncology nearing IND-enabling studies. The company has established collaborations with top pharma firms, providing non-dilutive funding and validation of its platform. Regor's AI platform enables rapid hit identification and lead optimization, potentially reducing cycle times and increasing success rates. While the company has not yet disclosed specific clinical data, its partner-backed approach reduces financial risk and leverages Big Pharma's development expertise. The convergence of AI-driven discovery and strategic out-licensing positions Regor as an attractive partner in the biotech ecosystem.

Upcoming Catalysts (preview)

• H2 2026Announcement of a major licensing deal for a lead oncology program50% success
• Q1 2027IND filing for a first-in-class metabolism candidate60% success
• Q3 2026Presentation of preclinical data for a novel immunology asset at a major conference80% success